CRMD — CorMedix Income Statement
0.000.00%
Last trade - 00:00
- $388.23m
- $342.62m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.283 | 0.239 | 0.191 | 0.065 | 0 |
Cost of Revenue | |||||
Gross Profit | -0.09 | 0.034 | 0.042 | 0.062 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 21.3 | 27.5 | 29.6 | 30.7 | 49 |
Operating Profit | -21 | -27.2 | -29.4 | -30.6 | -49 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -21.5 | -27.2 | -29.5 | -30.3 | -46.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.4 | -22 | -28.2 | -29.7 | -46.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.4 | -22 | -28.2 | -29.7 | -46.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -43.5 | -22 | -28.2 | -29.7 | -46.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.8 | -0.771 | -0.749 | -0.737 | -0.91 |